newsfilter
← Latest News
GlobeNewswire·

Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022

BOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced early clinical findings from its ongoing proof-of-concept study of investigational